Alteogen and Hanmi Pharmaceutical: A Hidden 'Record-Setting' Opportunity Amid Institutional Selling / NAVER's 300,000 Won Recovery Scenario? Why Now Is the Bottom | CEO Lee Kwon-hee
알테오젠·한미약품, 기관 투매 속 숨겨진 '역대급' 기회 / 네이버 30만 원 복귀 시나리오? 지금이 바닥인 이유 | 이권희 대표
Speakers
Lee Kwon-hee
— CEO, Economist
Summary
Lee Kwon-hee, CEO of Wizwave, reviewed several Korean stock and sector setups in a Q&A format. He viewed the recent biotech selloff as an oversold buying opportunity and highlighted specific catalysts for Alteogen, Hanmi Pharmaceutical, D&D Pharmatech, and ABL Bio. He also discussed Techwing, HD Korea Shipbuilding, NAVER, GS E&C, Seojin System, Samsung SDS, and Hyundai Motor, generally favoring patience and catalyst-driven positioning.
- Techwing's HBM inspection equipment orders are delayed, but January 29 Samsung and SK hynix earnings could revive semiconductor equipment sentiment.
- The Korean biotech selloff was called sentiment-driven, with Alteogen, Hanmi, ABL Bio, and D&D Pharmatech highlighted as fundamentally unchanged or catalyst-rich.
- Alteogen's option-contract queue and Hanmi and D&D MASH data are key biotech catalysts.
- HD Korea Shipbuilding and the shipbuilding sector were viewed positively for long-term holding.
- NAVER was called cheap with Coupang exodus, Naver Financial-Dunamu, and stablecoin catalysts.
- GS E&C and Seojin System were framed as waiting games with value-up or telecom and robot recovery catalysts.
- Samsung SDS was seen as boxed with limited catalysts; LG CNS was relatively preferred but also heavy.
- Hyundai Motor may be worth buying on a drop below 500,000 won, and cash was suggested for large-cap corrections.
Ideas
Hold Techwing into January 29 earnings catalyst.
Techwing rallied on expectations that its HBM inspection and probe-cube equipment would be supplied to Samsung and SK hynix, but actual orders have been delayed, so HBM equipment volume and earnings have not yet appeared. Micron qualification is still pending. The stock has already fallen enough, and the 120-week moving average should hold; the key catalyst is the January 29 Samsung Electronics and SK hynix earnings, where capex or expansion comments could revive semiconductor equipment and materials sentiment. Until then, he advises holding rather than selling.
Semiconductor equipment may reverse on capex news.
If Samsung Electronics and SK hynix give positive capex or expansion comments at their January 29 earnings, sentiment toward Korean semiconductor equipment and materials stocks could reverse after recent weakness, creating a trading opportunity in the broader materials and equipment theme.
Korean biotech selloff is a buying opportunity.
The recent indiscriminate selloff in Korean biotech, especially after Alteogen's decline and broader institutional selling, was driven by broken sentiment, rate and tariff worries, and inflation data rather than fundamental deterioration. Alteogen, Hanmi Pharmaceutical, ABL Bio, LigaChem Bio, and D&D Pharmatech are fundamentally unchanged, so the drop is a low-price buying opportunity.
Hanmi oversold with MASH and obesity catalysts.
Hanmi Pharmaceutical has been oversold. It could announce a large event, and its MASH treatment data was delayed because the trial recently ended and needs data organization, likely arriving in February or March. It has many pipelines, including domestic obesity treatment, oral obesity drugs, and a muscle-preservation mechanism in clinical trials, so upcoming results can lift the shares.
Alteogen's option queue supports patient buying.
Alteogen's fundamentals have not changed despite the sharp drop and institutional selling. It has about ten option contracts in the queue, with one GSK deal signed, leaving nine potential deals; the company controls the sequencing and can wait for better terms. The current weakness is therefore a sentiment-driven low-price buying opportunity, and investors should be patient.
ABL Bio tech export expected soon.
ABL Bio is expected to announce a technology export soon, as its CEO has said more deals should come within the year or early next year, likely tied to its BBB platform. This gives it a company-specific catalyst despite the sector selloff.
Buy D&D Pharmatech dips before data.
D&D Pharmatech is a MASH treatment expectation stock. The speaker advised accumulating on dips, saying the company is likely to make a major announcement by March, April, or at the latest May. Its clinical data are expected around March, management is confident, and the drop was due to sector selling rather than company problems.
Hold HD Korea Shipbuilding for another rally.
As an intermediate holding company, HD Korea Shipbuilding & Offshore Engineering moves slower than operating shipbuilders, but it is a favored shipbuilding name and should continue to rise over time. Its slope has flattened after a pullback, but it is preparing for another rally, so the speaker sees another leg up and a potential move above 500,000 won; hold.
Shipbuilding stocks can be 10% allocation.
The speaker says a roughly 10% portfolio allocation to shipbuilding stocks is acceptable, implying a positive long-term stance on the sector.
NAVER cheap with many upside catalysts.
NAVER is cheap at about 1.4x PBR and 16x PER for an internet company. The Coupang exodus is driving users back to NAVER shopping and partner platforms, while the Naver Financial-Dunamu merger and possible stablecoin inclusion for Naver Pay or Kakao Pay could create additional momentum; NAVER also owns a crypto exchange, which could create synergies. The stock has many catalysts, so the issue is when it breaks 300,000 won, not whether to sell.
GS E&C needs value-up to re-rate.
GS E&C is deeply undervalued at about 0.36x PBR, with okay earnings but limited momentum beyond housing construction. It lacks institutional support after past accounting issues. The key upside catalyst is a shareholder-return or value-up policy, possibly pressured by the National Pension Service as second-largest shareholder and by commercial law revisions; if such measures appear, the stock can re-rate. Until then, it is a waiting game.
Seojin can retest 36,000 on robot news.
Seojin System makes lightweight, durable aluminum cases and enclosures used in semiconductor equipment, ESS, and potentially robot bodies or covers. The stock has been moving with this year's expected return to profit, and if telecom equipment conditions improve or robot-related news attaches, it can revisit its prior high in the 36,000 won area, so holders should wait.
Samsung SDS boxed; LG CNS relatively better.
Samsung SDS is a Samsung Group SI company with stable logistics profits and group AI work, but revenue and operating profit are flat. It needs shareholder-return measures, yet it has almost no treasury shares, and a re-rating likely requires a major AI or logistics profit catalyst. The speaker would switch out at breakeven; if an investor must own an SI company, LG CNS looks relatively more attractive, though it is also heavy.
Samsung SDS boxed; LG CNS relatively better.
Samsung SDS is a Samsung Group SI company with stable logistics profits and group AI work, but revenue and operating profit are flat. It needs shareholder-return measures, yet it has almost no treasury shares, and a re-rating likely requires a major AI or logistics profit catalyst. The speaker would switch out at breakeven; if an investor must own an SI company, LG CNS looks relatively more attractive, though it is also heavy.
Buy Hyundai Motor below 500,000 won.
Hyundai Motor is showing a negative candle. If it falls below 500,000 won, it becomes attractive to buy on weakness, and the speaker suggests preparing cash for such a large-cap pullback.
Up Next
This 815 Money Talk (815머니톡) video, published January 22, 2026, features Lee Kwon-hee discussing 089030.KQ, Korean semiconductor equipment and materials sector, Korean biotech sector, 128940.KS, 196170.KQ, 298380.KQ, 347850.KQ, 009540.KS, Korean shipbuilding sector, 035420.KS, 006360.KS, 178320.KQ, 018260.KS, 064400.KS, 005380.KS. 15 trade ideas extracted by AI with direction and confidence scoring.
Speakers: Lee Kwon-hee · Tickers: 089030.KQ, Korean semiconductor equipment and materials sector, Korean biotech sector, 128940.KS, 196170.KQ, 298380.KQ, 347850.KQ, 009540.KS, Korean shipbuilding sector, 035420.KS, 006360.KS, 178320.KQ, 018260.KS, 064400.KS, 005380.KS